• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

    11/8/24 9:00:00 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SANA alert in real time by email

    Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology

    Enrolling patients in the investigator-sponsored trial with hypoimmune-modified primary islet cells, GLEAM trial for SC291 in B-cell mediated autoimmune diseases, and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect data from these studies in 2024 and/or 2025



    Announced increased focus on type 1 diabetes and B-cell mediated autoimmune diseases 



     Cash position of $199.0 million with expected cash runway into 2026

    SEATTLE, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the third quarter 2024.

    "Early clinical data with our hypoimmune technology suggest HIP-modified cells evade immune detection, and we look forward to sharing data in 2024 and 2025 across multiple clinical settings, including type 1 diabetes, B-cell mediated autoimmune diseases, and oncology," said Steve Harr, Sana's President and Chief Executive Officer. "This past quarter was an important one for the company, as we enhanced our leadership team with the addition of Dhaval Patel as our new Chief Scientific Officer, made progress with our clinical programs, and focused our pipeline. We are optimistic that our recent strategic repositioning to increase focus on immunologic diseases, particularly type 1 diabetes and B-cell mediated autoimmune diseases, will help accelerate development and prolong the capital runway for the company. We look forward to multiple clinical data readouts with our current balance sheet with our cash runway into 2026."

    Payments related to ongoing activities combined with the strategic repositioning may increase the 2024 operating cash burn above prior guidance of less than $200 million.

    Recent Corporate Highlights

    Advancing three clinical programs across five indications, including a gene-modified primary islet cell therapy in type 1 diabetes, an allogeneic CAR T program for B-cell mediated autoimmune diseases, and an allogeneic CAR T program for cancer patients that have failed a CD19-targeted therapy:

    • Type 1 Diabetes – UP421 is a primary human HIP-modified pancreatic islet cell therapy for patients with type 1 diabetes. The goal of this investigator-sponsored trial (IST) is to understand immune evasion, islet cell survival, and beta cell function, as measured by C-peptide production, of HIP-modified pancreatic islet cells in type 1 diabetics without any immunosuppression. Sana expects to share initial data in 2024 and/or 2025. Sana is also making progress with the pre-clinical development of SC451, a HIP-modified, stem cell-derived pancreatic islet cell program.
    • B-cell Mediated Autoimmune Diseases – The GLEAM trial evaluates SC291, a HIP-modified CD19-directed allogeneic CAR T therapy, in patients with B-cell mediated autoimmune diseases including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Sana is enrolling patients in this study and expects to share initial data in 2024 and/or 2025.
    • Oncology – The VIVID trial evaluates SC262, a HIP-modified CD22-directed allogeneic CAR T therapy, in patients with relapsed or refractory B-cell malignancies who have received prior CD19-directed CAR T therapy. Sana is enrolling patients and expects to share data in 2025.

    Strengthened Research and Development leadership with the appointment of new Chief Scientific Officer

    • Appointed Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Patel has decades of experience in research, drug discovery, drug development, and clinical care – including roles at UCB, Novartis, University of North Carolina, and the Duke University School of Medicine – and over the course of his career has participated in the development of 10 approved drugs in multiple indications.

    Third Quarter 2024 Financial Results

    GAAP Results

    • Cash Position: Cash, cash equivalents, and marketable securities as of September 30, 2024 were $199.0 million compared to $205.2 million as of December 31, 2023. The decrease of $6.2 million was primarily driven by cash used in operations of $176.0 million and cash used for the purchase of property and equipment of $33.0 million, partially offset by net proceeds from equity financings of $181.0 million, proceeds from stock option exercises and the employee stock purchase plan of $10.3 million, and net proceeds of $7.8 million from a loan to fund tenant improvements for our manufacturing facility in Bothell, Washington during the nine months ended September 30, 2024. 
    • Research and Development Expenses: For the three and nine months ended September 30, 2024, research and development expenses, inclusive of non-cash expenses, were $53.2 million and $170.5 million, respectively, compared to $65.6 million and $205.8 million for the same periods in 2023. The decreases of $12.4 million and $35.3 million for the three and nine months ended September 30, 2024, respectively, compared to the same periods in 2023 were primarily due to lower personnel-related and laboratory costs due to a decrease in headcount and decreased research costs related to the strategic repositioning in the fourth quarter of 2023, lower costs for third-party manufacturing at contract development and manufacturing organizations, and a decline in facility and other allocated costs. These decreases were partially offset by increased clinical development costs. Research and development expenses include non-cash stock-based compensation of $6.5 million and $19.5 million, respectively, for the three and nine months ended September 30, 2024 and $5.7 million and $18.4 million, for the same periods in 2023.
    • Research and Development Related Success Payments and Contingent Consideration: For the three and nine months ended September 30, 2024, Sana recognized a non-cash gain of $5.5 million and a non-cash expense of $4.6 million, respectively, in connection with the change in the estimated fair value of the success payment liabilities and contingent consideration in aggregate, compared to non-cash gains of $82.6 million and $55.8 million for the same periods in 2023. The value of these potential liabilities fluctuate significantly with changes in Sana's market capitalization and stock price.
    • General and Administrative Expenses: General and administrative expenses for the three and nine months ended September 30, 2024, inclusive of non-cash expenses, were $14.1 million and $46.8 million, respectively, compared to $19.2 million and $52.5 million for the same periods in 2023. The decreases of $5.1 million and $5.8 million for the three and nine months ended September 30, 2024, respectively, compared to the same periods in 2023 were primarily due to a decrease in costs related to Sana's previously planned manufacturing facility in Fremont, California, a decrease in legal and consulting fees, and lower personnel-related costs due to a decrease in headcount. These decreases were partially offset by an increase in non-cash stock-based compensation.
    • Net Loss: Net loss for the three and nine months ended September 30, 2024 was $59.9 million, or $0.25 per share, and $217.7 million, or $0.95 per share, respectively. Net income for the three months ended September 30, 2023 was $1.0 million, or $0.00 per share, and net loss for the nine months ended September 30, 2023 was $195.1 million, or $1.01 per share.

    Non-GAAP Measures

    • Non-GAAP Operating Cash Burn: Non-GAAP operating cash burn for the nine months ended September 30, 2024 was $153.1 million compared to $187.2 million for the same period in 2023. Non-GAAP operating cash burn is the decrease in cash, cash equivalents, and marketable securities, excluding cash inflows from financing activities, cash outflows from business development, non-recurring items, and the purchase of property and equipment.
    • Non-GAAP General and Administrative Expenses: Non-GAAP general and administrative expenses for the three and nine months ended September 30, 2024 were $14.1 million and $46.8 million, respectively, compared to $16.5 million and $49.8 million for the same periods in 2023. Non-GAAP general and administrative expenses for the three and nine months ended September 30, 2023 excludes the loss on termination of the Fremont lease.
    • Non-GAAP Net Loss: Non-GAAP net loss for the three and nine months ended September 30, 2024 was $64.7 million, or $0.27 per share, and $208.3 million, or $0.91 per share, respectively, compared to $79.0 million, or $0.41 per share, and $248.3 million, or $1.28 per share, for the same periods in 2023. Non-GAAP net loss excludes non-cash expenses and gains related to the change in the estimated fair value of contingent consideration and success payment liabilities, the impairment of other assets, and, for the three and nine months ended September 30, 2023, the loss on termination of the Fremont lease.

    A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under "Non-GAAP Financial Measures."

    About Sana

    Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws, including those related to the company's vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its preclinical, clinical and regulatory development plans and timing expectations; the potential ability of HIP-modified cells to evade immune detection; expectations regarding the timing, substance, significance, and impact of data from clinical trials of the Company's product candidates and an IST utilizing HIP-modified primary islet cells in patients with type 1 diabetes across multiple disease settings, including type 1 diabetes, B-cell mediated autoimmune diseases, and oncology; the potential of the strategic repositioning to help accelerate development and prolong the Company's capital runway; expectations regarding the Company's cash runway; and expectations regarding the Company's 2024 operating cash burn, including as a result of the strategic repositioning. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company's current and future research and development programs, preclinical and clinical trials, as well as economic, market, and social disruptions. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's Securities and Exchange Commission (SEC) reports, including but not limited to its Quarterly Report on Form 10-Q dated November 8, 2024. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

    Investor Relations & Media:

    Nicole Keith

    [email protected]

    [email protected]



    Sana Biotechnology, Inc.

    Unaudited Selected Consolidated Balance Sheet Data



     September 30, 2024  December 31, 2023 
     (in thousands) 
    Cash, cash equivalents, and marketable securities$199,007  $205,195 
    Total assets 559,392   565,299 
    Contingent consideration 111,856   109,606 
    Success payment liabilities 15,115   12,799 
    Total liabilities 266,914   277,793 
    Total stockholders' equity 292,478   287,506 





    Sana Biotechnology, Inc.

    Unaudited Consolidated Statements of Operations



     Three Months Ended

    September 30,
      Nine Months Ended

    September 30,
     
     2024  2023  2024  2023 
     (in thousands, except per share data) 
    Operating expenses:           
    Research and development$53,206  $65,613  $170,528  $205,823 
    Research and development related success payments and contingent consideration (5,497)  (82,615)  4,566   (55,816)
    General and administrative 14,052   19,183   46,763   52,515 
    Total operating expenses 61,761   2,181   221,857   202,522 
    Loss from operations (61,761)  (2,181)  (221,857)  (202,522)
    Interest income, net 2,579   2,862   8,815   7,212 
    Other income (expense), net (742)  303   (4,648)  172 
    Net income (loss)$(59,924) $984  $(217,690) $(195,138)
    Net income (loss) per common share – basic$(0.25) $0.00  $(0.95) $(1.01)
    Weighted-average number of common shares – basic 235,412   196,978   229,076   193,605 
    Net income (loss) per share – diluted$(0.25) $0.00  $(0.95) $(1.01)
    Weighted-average shares outstanding – diluted 235,412   200,473   229,076   193,605 





    Sana Biotechnology, Inc.

    Changes in the Estimated Fair Value of Success Payments and Contingent Consideration



     Success Payment

    Liability(1)
      Contingent

    Consideration(2)
      Total Success

    Payment Liability

    and Contingent

    Consideration
     
     (in thousands) 
    Liability balance as of December 31, 2023$12,799  $109,606  $122,405 
    Changes in fair value – expense 32,623   5,384   38,007 
    Liability balance as of March 31, 2024 45,422   114,990   160,412 
    Changes in fair value – gain (24,575)  (3,369)  (27,944)
    Liability balance as of June 30, 2024 20,847   111,621   132,468 
    Changes in fair value – expense (gain) (5,732)  235   (5,497)
    Liability balance as of September 30, 2024$15,115  $111,856  $126,971 
    Total change in fair value for the nine months ended September 30, 2024$2,316  $2,250  $4,566 



    (1)Cobalt Biomedicine, Inc. (Cobalt) and the Presidents and Fellows of Harvard College (Harvard) are entitled to success payments pursuant to the terms and conditions of their respective agreements. The success payments are recorded at fair value and remeasured at each reporting period with changes in the estimated fair value recorded in research and development related success payments and contingent consideration on the statement of operations.
    (2)Cobalt is entitled to contingent consideration upon the achievement of certain milestones pursuant to the terms and conditions of the agreement. Contingent consideration is recorded at fair value and remeasured at each reporting period with changes in the estimated fair value recorded in research and development related success payments and contingent consideration on the statement of operations.



    Non-GAAP Financial Measures

    To supplement the financial results presented in accordance with generally accepted accounting principles in the United States (GAAP), Sana uses certain non-GAAP financial measures to evaluate its business. Sana's management believes that these non-GAAP financial measures are helpful in understanding Sana's financial performance and potential future results, as well as providing comparability to peer companies and period over period. In particular, Sana's management utilizes non-GAAP operating cash burn, non-GAAP research and development expense and non-GAAP net loss and net loss per share. Sana believes the presentation of these non-GAAP measures provides management and investors greater visibility into the company's actual ongoing costs to operate its business, including actual research and development costs unaffected by non-cash valuation changes and certain one-time expenses for acquiring technology, as well as facilitating a more meaningful comparison of period-to-period activity. Sana excludes these items because they are highly variable from period to period and, in respect of the non-cash expenses, provides investors with insight into the actual cash investment in the development of its therapeutic programs and platform technologies.

    These are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with Sana's financial statements prepared in accordance with GAAP. These non-GAAP measures differ from GAAP measures with the same captions, may be different from non-GAAP financial measures with the same or similar captions that are used by other companies, and do not reflect a comprehensive system of accounting. Sana's management uses these supplemental non-GAAP financial measures internally to understand, manage, and evaluate Sana's business and make operating decisions. In addition, Sana's management believes that the presentation of these non-GAAP financial measures is useful to investors because they enhance the ability of investors to compare Sana's results from period to period and allows for greater transparency with respect to key financial metrics Sana uses in making operating decisions. The following are reconciliations of GAAP to non-GAAP financial measures:



    Sana Biotechnology, Inc.

    Unaudited Reconciliation of Change in Cash, Cash Equivalents, and Marketable Securities to

    Non-GAAP Operating Cash Burn



     Nine Months Ended September 30, 
     2024  2023 
     (in thousands) 
    Beginning cash, cash equivalents, and marketable securities$205,195  $434,014 
    Ending cash, cash equivalents, and marketable securities 199,007   268,570 
    Change in cash, cash equivalents, and marketable securities (6,188)  (165,444)
    Cash paid to purchase property and equipment 32,994   5,986 
    Change in cash, cash equivalents, and marketable securities, excluding capital expenditures 26,806   (159,458)
    Adjustments:     
    Net proceeds from issuance of common stock (181,000)  (27,009)
    Cash paid for personnel-related costs related to portfolio prioritizations 1,110   1,881 
    Cash paid in connection with the termination of the Fremont lease -   4,423 
    Cash received in connection with the Coronavirus Aid, Relief, and Economic Security Act -   (7,063)
    Operating cash burn – Non-GAAP$(153,084) $(187,226)





    Sana Biotechnology, Inc.

    Unaudited Reconciliation of GAAP to Non-GAAP General and Administrative Expense



     Three Months Ended

    September 30,
      Nine Months Ended

    September 30,
     
     2024  2023  2024  2023 
     (in thousands) 
    General and administrative – GAAP$14,052  $19,183  $46,763  $52,515 
    Adjustments:           
    Loss on termination of Fremont lease(1) -   (2,668)  -   (2,668)
    General and administrative – Non-GAAP$14,052  $16,515  $46,763  $49,847 



    (1)For the three and nine months ended September 30, 2023, the loss of $2.7 million included $4.4 million in fees incurred, offset by a gain of $1.7 million recorded in connection with the derecognition of the right-of use asset and lease liability associated with the Fremont Facility.





    Sana Biotechnology, Inc.

    Unaudited Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss Per Share



     Three Months Ended

    September 30,
      Nine Months Ended

    September 30,
     
     2024  2023  2024  2023 
     (in thousands, except per share data) 
    Net income (loss) – GAAP$(59,924) $984  $(217,690) $(195,138)
    Adjustments:           
    Change in the estimated fair value of the success payment liabilities(1) (5,732)  (24,037)  2,316   (8,593)
    Change in the estimated fair value of contingent consideration(2) 235   (58,578)  2,250   (47,223)
    Loss on termination of Fremont lease(3) -   2,668   -   2,668 
    Impairment of other assets 763   -   4,832   - 
    Net loss – Non-GAAP$(64,658) $(78,963) $(208,292) $(248,286)
    Net income (loss) per share – GAAP$(0.25) $-  $(0.95) $(1.01)
    Adjustments:           
    Change in the estimated fair value of the success payment liabilities(1) (0.02)  (0.12)  0.01   (0.04)
    Change in the estimated fair value of contingent consideration(2) -   (0.30)  0.01   (0.24)
    Loss on termination of Fremont lease(3) -   0.01   -   0.01 
    Impairment of other assets -   -   0.02   - 
    Net loss per share – Non-GAAP$(0.27) $(0.41) $(0.91) $(1.28)
    Weighted-average shares outstanding – basic 235,412   196,978   229,076   193,605 



    (1)For the three months ended September 30, 2024, the gain related to the Cobalt success payment liability was $4.9 million compared to $22.0 million for the same period in 2023. For the nine months ended September 30, 2024, the expense related to the Cobalt success payment liability was $2.3 million compared to a gain of $8.3 million for the same period in 2023. For the three months ended September 30, 2024, the gain related to the Harvard success payment liabilities was $0.8 million compared to $2.0 million for the same period in 2023. For the nine months ended September 30, 2024, the gain related to the Harvard success payment liabilities was immaterial compared to a gain of $0.3 million for the same period in 2023.
    (2)The contingent consideration is in connection with the acquisition of Cobalt.
    (3)For the three and nine months ended September 30, 2023, the loss of $2.7 million included $4.4 million in fees incurred, offset by a gain of $1.7 million recorded in connection with the derecognition of the right-of use asset and lease liability associated with the Fremont Facility.


    Primary Logo

    Get the next $SANA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SANA

    DatePrice TargetRatingAnalyst
    7/3/2025$12.00Overweight
    Morgan Stanley
    3/18/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    3/14/2025$7.00Buy
    Jefferies
    1/8/2025Hold → Buy
    TD Cowen
    11/5/2024Mkt Outperform → Mkt Perform
    JMP Securities
    6/26/2024$16.00Buy
    Rodman & Renshaw
    1/16/2024$12.00Neutral → Buy
    H.C. Wainwright
    9/25/2023$9.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $SANA
    SEC Filings

    See more
    • Sana Biotechnology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

      6/23/25 10:10:46 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sana Biotechnology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

      6/6/25 4:05:17 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Sana Biotechnology Inc.

      424B5 - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:44:44 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

      Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous prod

      7/1/25 6:30:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

      SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking p

      6/9/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sana Biotechnology to Present at June 2025 Investor Conferences

      SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update. Sana will present at the Jefferies Global Healthcare Conference at 2:35 p.m. ET on Wednesday, June 4, 2025.Sana will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 10, 2025. The webcasts will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of each presentation will be availa

      5/28/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:46:20 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Crandell Keith bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:43:56 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arch Venture Fund X, L.P. bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:43:09 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Sana Biotechnology with a new price target

      Morgan Stanley resumed coverage of Sana Biotechnology with a rating of Overweight and set a new price target of $12.00

      7/3/25 7:51:55 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sana Biotechnology upgraded by Citizens JMP with a new price target

      Citizens JMP upgraded Sana Biotechnology from Mkt Perform to Mkt Outperform and set a new price target of $5.00

      3/18/25 7:56:06 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Sana Biotechnology with a new price target

      Jefferies initiated coverage of Sana Biotechnology with a rating of Buy and set a new price target of $7.00

      3/14/25 7:41:20 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bishop Hans Edgar was granted 7,842 shares, increasing direct ownership by 0.13% to 5,828,955 units (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      7/8/25 4:17:31 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Rosiello Robert L.

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      6/9/25 4:40:33 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Bilenker Joshua H.

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      6/9/25 4:40:28 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Leadership Updates

    Live Leadership Updates

    See more
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B cell depletion using a surrogate for SG299, an in viv

      3/17/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Financials

    Live finance-specific insights

    See more
    • Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

      First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT) MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation Study Contin

      1/7/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 5:12:32 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 6:00:14 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/12/24 4:52:24 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care